Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
Skip Navigation LinksHome > Kinase Inhibitors > c-Met > MGCD516 (Sitravatinib)
MGCD516 (Sitravatinib)
MGCD516 is a clinical stage, orally available and potent small molecule inhibitor, targeting a closely related family of Receptor Tyrosine Kinases (RTKs) including RET, TRK, DDR2, MET, Axl , KIT, as well as VEGFR and PDGFR family members. RTKs inhibited by MGCD516 are genetically altered in a variety of cancers, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), functioning as oncogenic drivers promoting cancer development and progression. Alterations in these RTKs have also been implicated in tumor resistance mechanisms. MGCD516 has demonstrated broad antitumor activity including demonstration of tumor regression in preclinical models harboring genetic dysregulation of MGCD516 targets including MET amplification, METex14del, RET rearrangement and CHR4q12 amplification. It is currently in clinical evaluations.
Catalog NO: CT-MG516
Synonym: Sitravatinib, MG516
CAS NO: 1123837-84-2
Mol. Formula: C33H29F2N5O4S∙ 0.3H2O
MW: 635.1
** >98.5% purity (by HPLC at 214 and 254 nm), with clean Quantitative Elemental Analysis. Grams in stock from Indianapolis USA. Ship within 1 day.